Comparison of Bordetella species identification among differing rt-PCR assays in the United States
Microbiology Spectrum · 06.08.2024 · 12 (8)
DOI: 10.1128/spectrum.00783-24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Microbiology Spectrum, erschienen am 06.08.2024. Verfasst von Matthew Cole und 7 weiteren Autor:innen. Beteiligte Einrichtung: Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Center…. Hauptthemen laut MEDLINE: Bordetella, Real-Time Polymerase Chain Reaction, Bordetella Infections, Bordetella pertussis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | Centers for Disease Control and Prevention (CDC).
Abstract (Originalsprache)
In the United States, the general laboratory method for diagnosing pertussis, caused by Bordetella pertussis, is real-time PCR (rt-PCR) targeting insertion sequence 481 (IS 481 ). Other Bordetella species ( parapertussis, holmesii , and bronchiseptica ) can also cause a pertussis-like syndrome, and some commercial laboratory assays include the insertion sequence 1001 (pIS 1001 ) that can detect B. parapertussis / B. bronchiseptica (BppBb ). Because IS 481 exists in B. pertussis and B. holmesii , current commercial assays cannot differentiate these two species. We used a multiplex rt-PCR assay containing species-specific targets to Bordetella to evaluate clinical specimens detected as B. pertussis / B. holmesii ( BpBh ) or BppBb by commercial laboratories. A sample of 3,984 clinical specimens positive for IS 481 or pIS 1001 from two commercial laboratories during 2012–2019 were re-tested at CDC. Agreement of Bordetella species between the CDC and commercial laboratory assays, and the proportion of commercial laboratory specimens that were non- B . pertussis by CDC’s assay was assessed. Overall agreement in Bordetella species detection and identification between the CDC and commercial lab assays was 85%. Agreement for identifying B. pertussis was 87% for 3,663 BpBh specimens and 98% for identifying B. parapertussis in 310 BppBb specimens. CDC’s assay detected B. holmesii in 55/3,984 (1.4%) specimens. Most discrepant results (410/490, 82%) were BpBh specimens interpreted as indeterminate B. pertussis at CDC. We found a small portion of B. holmesii in a sample of IS 481 -positive clinical specimens originally identified by commercial laboratory rt-PCR assays, suggesting that commercial PCR assays are a reliable diagnostic tool for correctly identifying Bordetella species in most patients with suspected pertussis. IMPORTANCE When testing specimens collected from patients with suspected pertussis, large-scale commercial laboratories in the United States employ an IS 481 -based assay that cannot differentiate between Bordetella pertussis and Bordetella holmseii . The level of B. holmesii causing pertussis-like illness in the United States is not well-understood given that only B. pertussis is nationally notifiable. After re-testing with a multiplex, species-specific rt-PCR assay, our data show low levels of B. holmesii identified in a sample of IS 481 -positive clinical specimens originally identified by commercial laboratory rt-PCR assays. These results reinforce the validity of large-scale commercial rt-PCR testing as a reliable diagnostic tool for pertussis in the United States.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Division of Parasitic Diseases and Malaria, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Oregon Health Authority, Portland, Oregon, USA.
- Quest Diagnostics, San Juan Capistrano, California, USA.
- Labcorp, Burlington, North Carolina, USA.
ORCID-Profile: Matthew Cole
Förderung
- HHS | Centers for Disease Control and Prevention (CDC)
Zitieren
APA
Cole, M., Simon, A. K., Faulkner, A., Skoff, T., Tondella, M. L., Montero, C., Nye, M. B., & Williams, M. (2024). Comparison of Bordetella species identification among differing rt-PCR assays in the United States. Microbiology Spectrum, 12(8). https://doi.org/10.1128/spectrum.00783-24
Vancouver
Cole M, Simon AK, Faulkner A, Skoff T, Tondella ML, Montero C, et al. Comparison of Bordetella species identification among differing rt-PCR assays in the United States. Microbiology Spectrum. 2024;12(8). doi:10.1128/spectrum.00783-24
BibTeX
@article{Cole2024,
author = {Cole, Matthew and Simon, Ashley K and Faulkner, Amanda and Skoff, Tami and Tondella, Maria L and Montero, Clemente and Nye, Melinda B and Williams, Margaret},
title = {Comparison of Bordetella species identification among differing rt-PCR assays in the United States},
journal = {Microbiology Spectrum},
year = {2024},
volume = {12},
number = {8},
doi = {10.1128/spectrum.00783-24}
}
EUVIMED